EMFAT
AIMT

Emerald Mutual Fund Advisers Trust’s Aimmune Therapeutics AIMT Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-491,790
Closed -$8.22M – 376
2020
Q2 		$8.22M Buy
491,790
+13,447
+3% +$228K 0.39% 93
2020
Q1 		$6.9M Sell
478,343
-109,121
-19% -$2.79M 0.43% 83
2019
Q4 		$19.7M Hold
587,464
– – 0.8% 43
2019
Q3 		$12.3M Sell
587,464
-189,479
-24% -$3.87M 0.54% 66
2019
Q2 		$16.2M Hold
776,943
– – 0.64% 53
2019
Q1 		$17.4M Buy
776,943
+128,014
+20% +$3.01M 0.7% 50
2018
Q4 		$15.5M Buy
648,929
+187,380
+41% +$4.85M 0.73% 47
2018
Q3 		$12.6M Buy
461,549
+64,467
+16% +$1.82M 0.43% 93
2018
Q2 		$10.7M Sell
397,082
-749
-0.2% -$22.9K 0.39% 102
2018
Q1 		$12.7M Buy
397,831
+749
+0.2% +$26.4K 0.5% 72
2017
Q4 		$15M Sell
397,082
-54,578
-12% -$1.76M 0.6% 58
2017
Q3 		$11.2M Sell
451,660
-7,500
-2% -$162K 0.47% 78
2017
Q2 		$9.44M Hold
459,160
– – 0.41% 88
2017
Q1 		$9.98M Sell
459,160
-148,096
-24% -$3.04M 0.46% 76
2016
Q4 		$12.4M Buy
607,256
+189,042
+45% +$3.86M 0.59% 62
2016
Q3 		$6.27M Buy
418,214
+85,589
+26% +$1.16M 0.32% 115
2016
Q2 		$3.6M Buy
332,625
+3,970
+1% +$53.9K 0.2% 139
2016
Q1 		$4.46M Buy
328,655
+46,300
+16% +$722K 0.25% 122
2015
Q4 		$5.21M Buy
282,355
+242,075
+601% +$4.48M 0.28% 115
2015
Q3 		$1.02M Buy
+40,280
New +$942K 0.07% 184

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's AIMT Position: Q3 2020 in Review

Emerald Mutual Fund Advisers Trust sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 491,790 shares — an estimated $8.22M sold.

Emerald Mutual Fund Advisers Trust first reported a position in AIMT in Q3 2015 and held it in 20 quarters. The position peaked at $19.7M in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Emerald Mutual Fund Advisers Trust reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 491,790 Aimmune Therapeutics shares in Q3 2020, an estimated $8.22M.
  • Emerald Mutual Fund Advisers Trust first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 20 quarters.
  • Emerald Mutual Fund Advisers Trust's Aimmune Therapeutics position peaked at $19.7M in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q3 2020, filed 28 Oct 2020.